Literature DB >> 23416144

Cysteamine: an old drug with new potential.

Martine Besouw1, Rosalinde Masereeuw, Lambert van den Heuvel, Elena Levtchenko.   

Abstract

Cysteamine is an amino thiol with the chemical formula HSCH2CH2NH2. Endogenously, cysteamine is derived from coenzyme A degradation, although its plasma concentrations are low. Most experience with cysteamine as a drug originates from the field of the orphan disease cystinosis, in which cysteamine is prescribed to decrease intralysosomal cystine accumulation. However, over the years, the drug has been used for several other applications both in vitro and in vivo. In this article, we review the different applications of cysteamine, ending with an overview of ongoing clinical trials for new indications, such as neurodegenerative disorders and nonalcoholic fatty liver disease (NAFLD). The recent development of an enteric-coated cysteamine formulation makes cysteamine more patient friendly and will extend its applicability for both old and new indications.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416144     DOI: 10.1016/j.drudis.2013.02.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  35 in total

1.  Fe2+-Mediated Activation of BKCa Channels by Rapid Photolysis of CORM-S1 Releasing CO and Fe2.

Authors:  Guido Gessner; Philipp Rühl; Matthias Westerhausen; Toshinori Hoshi; Stefan H Heinemann
Journal:  ACS Chem Biol       Date:  2020-07-29       Impact factor: 5.100

Review 2.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 3.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

4.  Geraniol-a flavoring agent with multifunctional effects in protecting the gastric and duodenal mucosa.

Authors:  Katharinne Ingrid Moraes de Carvalho; Flavia Bonamin; Raquel Cássia Dos Santos; Larissa Lucena Périco; Fernando Pereira Beserra; Damião Pergentino de Sousa; José Maria Barbosa Filho; Lucia Regina Machado da Rocha; Clelia Akiko Hiruma-Lima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-17       Impact factor: 3.000

Review 5.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

Review 6.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

7.  Cysteamine alleviates early brain injury via reducing oxidative stress and apoptosis in a rat experimental subarachnoid hemorrhage model.

Authors:  Zong-Yong Zhang; Ming-Feng Yang; Tao Wang; Da-Wei Li; Yun-Lin Liu; Jin-Hui Zhang; Bao-Liang Sun
Journal:  Cell Mol Neurobiol       Date:  2014-12-20       Impact factor: 5.046

8.  Metabolic interactions between cysteamine and epigallocatechin gallate.

Authors:  Valentina Izzo; Federico Pietrocola; Valentina Sica; Sylvère Durand; Sylvie Lachkar; David Enot; José Manuel Bravo-San Pedro; Alexis Chery; Speranza Esposito; Valeria Raia; Luigi Maiuri; Maria Chiara Maiuri; Guido Kroemer
Journal:  Cell Cycle       Date:  2017-01-06       Impact factor: 4.534

9.  Impact of atypical mitochondrial cyclic-AMP level in nephropathic cystinosis.

Authors:  Francesco Bellomo; Anna Signorile; Grazia Tamma; Marianna Ranieri; Francesco Emma; Domenico De Rasmo
Journal:  Cell Mol Life Sci       Date:  2018-03-16       Impact factor: 9.261

10.  Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions.

Authors:  Corinne Inauen; Véronique Rüfenacht; Amit V Pandey; Liyan Hu; Henk Blom; Jean-Marc Nuoffer; Johannes Häberle
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.